Heparin-induced thrombocytopenia with very high antibody titer is associated with slower platelet recovery and higher risk of thrombosis.
HIT
Heparin–PF4 antibodies
Platelet recovery time
Thrombosis
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
08 Jul 2024
08 Jul 2024
Historique:
received:
10
09
2023
accepted:
24
06
2024
revised:
06
06
2024
medline:
8
7
2024
pubmed:
8
7
2024
entrez:
8
7
2024
Statut:
aheadofprint
Résumé
Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder mediated by platelet-activating antibodies targeting platelet factor 4 (PF4) and heparin complex. A higher antibody titer is reflected in a higher optical density (OD) by enzyme-linked immunosorbent assay for heparin-PF4 antibodies. This single-institution retrospective study of 116 HIT patients examined the effect of heparin-PF4 OD on time to platelet recovery, vascular thrombosis, and in-hospital mortality. Patients were divided into 3 cohorts based on heparin-PF4 OD: cohort 1 had an OD ≥ 2 and ≤ 2.4, cohort 2 had an OD > 2.4 and ≤ 2.8, and cohort 3 had an OD > 2.8. A higher OD titer was associated with significantly increased time to platelet recovery when compared between cohorts 1 versus 2 (HR = 0.599, p = 0.0221) and 1 versus 3 (HR = 0.515, p = 0.0014), as well as an increased risk of thrombosis (79.4%-cohort 3 vs 53.8%-cohort 2 vs 46.1%-cohort 1, p = 0.04), but had no impact on mortality (2.62-alive vs 2.65-deceased, p = 0.7432). A higher OD titer can inform risk assessment and support decision-making in HIT patients; however, prospective studies are needed to further clarify the impact of heparin-PF4 OD on outcomes.
Identifiants
pubmed: 38976179
doi: 10.1007/s12185-024-03811-2
pii: 10.1007/s12185-024-03811-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Japanese Society of Hematology.
Références
Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost. 2008;6(8):1304–12.
doi: 10.1111/j.1538-7836.2008.03025.x
pubmed: 18489711
Warkentin TE, Sheppard JAI. Testing for heparin-induced thrombocytopenia antibodies. Transfus Med Rev. 2006;20(4):259–72.
doi: 10.1016/j.tmrv.2006.05.001
pubmed: 17008164
Zwicker JI, Uhl L, Huang WY, Shaz BH, Bauer KA. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost. 2004;2(12):2133–7.
doi: 10.1111/j.1538-7836.2004.01039.x
pubmed: 15613017
Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med. 1999;106(6):629–35.
doi: 10.1016/S0002-9343(99)00124-2
pubmed: 10378620
Rice L. Cases of heparin-induced thrombocytopenia elucidate the syndrome. Chest. 2005;127(2):21S-26S.
doi: 10.1378/chest.127.2_suppl.21S
pubmed: 15706027
Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med. 2001;138(1):22–31.
doi: 10.1067/mlc.2001.115525
pubmed: 11433225
Eichler P, Raschke R, Lubenow N, Meyer O, Schwind P, Greinacher A. The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays: ID-heparin/PF4 antibody test for detection of HIT antibodies. Br J Haematol. 2002;116(4):887–91.
doi: 10.1046/j.0007-1048.2002.03363.x
pubmed: 11886396
Legnani C, Cini M, Pili C, Boggian O, Frascaro M, Palareti G. Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparin-induced thrombocytopenia. Thromb Haemost. 2010;104(08):402–9.
doi: 10.1160/TH10-01-0002
pubmed: 20539902
Juhl D, Eichler P, Lubenow N, Strobel U, Wessel A, Greinacher A. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol. 2006;76(5):420–6.
doi: 10.1111/j.1600-0609.2005.00621.x
pubmed: 16466367
Francis J. A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex. Semin Thromb Hemost. 2004;30(03):359–68.
doi: 10.1055/s-2004-831049
pubmed: 15282659
Padmanabhan A, Jones C, Curtis BR, Bougie DW, Sullivan M, Peswani N, et al. A novel PF4-dependent platelet activation assay identifies patients likely to have heparin-induced thrombocytopenia/thrombosis (HIT). Blood. 2015;126(23):764–764.
doi: 10.1182/blood.V126.23.764.764
Marchetti M, Zermatten MG, Bertaggia Calderara D, Aliotta A, Alberio L. Heparin-induced thrombocytopenia: a review of new concepts in pathogenesis, diagnosis, and management. J Clin Med. 2021;10(4):683.
doi: 10.3390/jcm10040683
pubmed: 33578859
pmcid: 7916628
Greinacher A. Heparin-induced thrombocytopenia. Solomon CG, editor. N Engl J Med. 2015;373(3):252–61.
doi: 10.1056/NEJMcp1411910
pubmed: 26176382
Warkentin TE, Anderson JAM. How I treat patients with a history of heparin-induced thrombocytopenia. Blood. 2016;128(3):348–59.
doi: 10.1182/blood-2016-01-635003
pubmed: 27114458
Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. Annu Rev Med. 2010;61(1):77–90.
doi: 10.1146/annurev.med.042808.171814
pubmed: 20059332
pmcid: 4153429
Cuker A, Cines DB. How I treat heparin-induced thrombocytopenia. Blood. 2012;119(10):2209–18.
doi: 10.1182/blood-2011-11-376293
pubmed: 22246036
Thorevska N, Amoateng-Adjepong Y, Sabahi R, Schiopescu I, Salloum A, Muralidharan V, et al. Anticoagulation in hospitalized patients with renal insufficiency. Chest. 2004;125(3):856–63.
doi: 10.1378/chest.125.3.856
pubmed: 15006942
Hughes S, Szeki I, Nash MJ, Thachil J. Anticoagulation in chronic kidney disease patients—the practical aspects. Clin Kidney J. 2014;7(5):442–9.
doi: 10.1093/ckj/sfu080
pubmed: 25878775
pmcid: 4379338
Warkentin TE, Pai M, Linkins LA. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. Blood. 2017;130(9):1104–13.
doi: 10.1182/blood-2017-04-778993
pubmed: 28646118
Tardy-Poncet B, Piot M, Montmartin A, Burdier A, Chalayer E, Tardy B. Delayed-onset heparin-induced thrombocytopenia without thrombosis in a patient receiving postoperative thromboprophylaxis with rivaroxaban. Thromb Haemost. 2015;114(09):652–4.
doi: 10.1160/TH14-07-0593
pubmed: 26062524
Linkins LA, Warkentin TE, Pai M, Shivakumar S, Manji RA, Wells PS, et al. Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study. J Thromb Haemost. 2016;14(6):1206–10.
doi: 10.1111/jth.13330
pubmed: 27061271
Sharifi M, Bay C, Vajo Z, Freeman W, Sharifi M, Schwartz F. New oral anticoagulants in the treatment of heparin-induced thrombocytopenia. Thromb Res. 2015;135(4):607–9.
doi: 10.1016/j.thromres.2015.01.009
pubmed: 25613925
Larsen PB, Jørgensen M, Friis-Hansen L, Ingeberg S. Apixaban used for the management of heparin-induced thrombocytopenia in a 72-year-old woman with lung cancer. Clin Case Rep. 2015;3(12):987–9.
doi: 10.1002/ccr3.411
pubmed: 26732728
pmcid: 4693689
Delgado-García G, Monreal-Robles R. Acute apixaban treatment of heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2017;43(3):289–90.
doi: 10.1007/s11239-016-1458-9
pubmed: 27844303
Anniccherico FJ, Alonso JL. Dabigatran for heparin-induced thrombocytopenia. Mayo Clin Proc. 2013;88(9):1036.
doi: 10.1016/j.mayocp.2013.06.013
pubmed: 24001499
Noel E, Abbas N, Skaradinskiy Y, Schreiber Z. Heparin-induced thrombocytopenia in a patient with essential thrombocythemia: a case based update. Case Rep Hematol. 2015;2015:1–5.
doi: 10.1155/2015/985253
Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360–92.
doi: 10.1182/bloodadvances.2018024489
pubmed: 30482768
pmcid: 6258919
Altuntas F, Matevosyan K, Burner J, Shen YM, Sarode R. Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia. Eur J Haematol. 2008;80(5):429–35.
doi: 10.1111/j.1600-0609.2008.01035.x
pubmed: 18208574
Baroletti S, Hurwitz S, Conti NAS, Fanikos J, Piazza G, Goldhaber SZ. Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels. Am J Med. 2012;125(1):44–9.
doi: 10.1016/j.amjmed.2011.06.025
pubmed: 22075045
Warkentin T, Hayward C, Boshkov L, Santos A, Sheppard J, Bode A, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84(11):3691–9.
doi: 10.1182/blood.V84.11.3691.bloodjournal84113691
pubmed: 7949124
Arman M, Krauel K. Human platelet IgG Fc receptor FcγRIIA in immunity and thrombosis. J Thromb Haemost. 2015;13(6):893–908.
doi: 10.1111/jth.12905
pubmed: 25900780
Rauova L, Hirsch JD, Greene TK, Zhai L, Hayes VM, Kowalska MA, et al. Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood. 2010;116(23):5021–31.
doi: 10.1182/blood-2010-03-276964
pubmed: 20724543
pmcid: 3012595
Kasthuri RS, Glover SL, Jonas W, McEachron T, Pawlinski R, Arepally GM, et al. PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI. Blood. 2012;119(22):5285–93.
doi: 10.1182/blood-2011-06-359430
pubmed: 22394597
pmcid: 3369617
Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med. 1987;316(10):581–9.
doi: 10.1056/NEJM198703053161004
pubmed: 3807952
Brandt S, Krauel K, Gottschalk KE, Renné T, Helm CA, Greinacher A, et al. Characterisation of the conformational changes in platelet factor 4 induced by polyanions: towards in vitro prediction of antigenicity. Thromb Haemost. 2014;112(07):53–64.
doi: 10.1160/TH13-08-0634
pubmed: 24671506
Ziporen L, Li ZQ, Park KS, Sabnekar P, Liu WY, Arepally G, et al. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood. 1998;92(9):3250–9.
doi: 10.1182/blood.V92.9.3250
pubmed: 9787161
Zheng Y, Yu M, Podd A, Yuan L, Newman DK, Wen R, et al. Critical role for mouse marginal zone B cells in PF4/heparin antibody production. Blood. 2013;121(17):3484–92.
doi: 10.1182/blood-2013-01-477091
pubmed: 23460609
pmcid: 3637017